These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36270925)

  • 21. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
    Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
    Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
    Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
    BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy.
    Golfieri R; Mosconi C; Giampalma E; Cappelli A; Galaverni MC; Pettinato C; Renzulli M; Monari F; Mazzarotto R; Pinto C; Angelelli B
    Radiol Med; 2015 Aug; 120(8):767-76. PubMed ID: 25678128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy.
    Gunduz S; Ozgur O; Bozcuk H; Coşkun HS; Ozdogan M; Erkilic M; Sindel T; Yldlzs A; Ylmaz S; Boz A; Aydin F; Karayalçin B; Savas B
    Hepatogastroenterology; 2014 Sep; 61(134):1529-34. PubMed ID: 25436337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
    Sangro B; Carpanese L; Cianni R; Golfieri R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Van Buskirk M; Bilbao JI; Ettorre GM; Salvatori R; Giampalma E; Geatti O; Wilhelm K; Hoffmann RT; Izzo F; Iñarrairaegui M; Maini CL; Urigo C; Cappelli A; Vit A; Ahmadzadehfar H; Jakobs TF; Lastoria S;
    Hepatology; 2011 Sep; 54(3):868-78. PubMed ID: 21618574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
    Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
    Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicity and Survival of Hepatocellular Carcinoma Patients with Hepatitis B Infection Treated with Yttrium-90 Radioembolization: An Updated 15-Year Study.
    Gao R; Gabr A; Mouli S; Riaz A; Kulik L; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2020 Mar; 31(3):401-408.e1. PubMed ID: 31983593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
    Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study.
    White J; Carolan-Rees G; Dale M; Patrick HE; See TC; Bell JK; Manas DM; Crellin A; Slevin NJ; Sharma RA
    J Vasc Interv Radiol; 2019 Aug; 30(8):1185-1192. PubMed ID: 31255499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres.
    Carpizo DR; Gensure RH; Yu X; Gendel VM; Greene SJ; Moore DF; Jabbour SK; Nosher JL
    J Vasc Interv Radiol; 2014 Feb; 25(2):297-306.e1. PubMed ID: 24360887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study.
    Abdallah MA; Wongjarupong N; Hassan MA; Taha W; Abdalla A; Bampoh S; Onyirioha K; Nelson M; Glubranson LA; Wiseman GA; Fleming CJ; Andrews JC; Mahipal A; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2020 Jul; 14(7):619-629. PubMed ID: 32490691
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Kurilova I; Beets-Tan RGH; Ulaner GA; Boas FE; Petre EN; Yarmohammadi H; Ziv E; Deipolyi AR; Brody LA; Gonen M; Sofocleous CT
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1419-1427. PubMed ID: 29766239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases.
    Faron A; Pieper CC; Schmeel FC; Sprinkart AM; Kuetting DLR; Fimmers R; Trebicka J; Schild HH; Meyer C; Thomas D; Luetkens JA
    Eur Radiol; 2019 Sep; 29(9):4709-4717. PubMed ID: 30689036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
    Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
    J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter Evaluation of Survival and Toxicities of Hepatocellular Carcinoma following Radioembolization: Analysis of the RESiN Registry.
    Frantz S; Matsuoka L; Vaheesan K; Petroziello M; Golzarian J; Wang E; Gandhi R; Collins Z; Brower J; Rachakonda VM; Du L; Kennedy AS; Sze DY; Lee J; Brown DB
    J Vasc Interv Radiol; 2021 Jun; 32(6):845-852. PubMed ID: 33812981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yttrium-90 Radioembolization for Liver-Dominant Metastatic Prostate Cancer: A Case Series.
    Bibok A; Kis B; Frakes J; Hoffe S; Zhang J; Jain R; Parikh N
    J Vasc Interv Radiol; 2022 Sep; 33(9):1061-1065. PubMed ID: 36049841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.